

Nivolumab + ipilimumab vs EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: final results of CheckMate 651


<u>Athanassios Argiris</u>,^{1,2} Kevin Harrington,³ Makoto Tahara,⁴ Robert L. Ferris,⁵ Maura Gillison,⁶ Jerome Fayette,⁷ Amaury Daste,⁸ Piotr Koralewski,⁹ Ricard Mesia,¹⁰ Nabil F. Saba,¹¹ Milena Mak,¹² Miguel Angel Álvarez Avitia,¹³ Alexander Guminski,¹⁴ Urs Müller-Richter,¹⁵ Naomi Kiyota,¹⁶ Mustimbo Roberts,¹⁷ Tariq Aziz Khan,¹⁷ Karen Miller-Moslin,¹⁷ Li Wei,¹⁷ Robert Haddad¹⁸

¹Hygeia Hospital, Marousi, Greece; ²Thomas Jefferson University, Philadelphia, PA, USA; ³Royal Marsden Hospital/The Institute of Cancer Research, London, UK; ⁴National Cancer Center Hospital East, Kashiwa, Japan; ⁵UPMC Hillman Cancer Center, Pittsburgh, PA, USA; ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁷Centre Léon Bérard, Lyon, France; ⁸Hôpital Saint-André, Bordeaux, France; ⁹Wojewodzki Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Krakow, Poland; ¹⁰Catalan Institut of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; ¹¹Winship Cancer Institute of Emory University, Atlanta, GA, USA; ¹²Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; ¹³Instituto Nacional De Cancerología, Mexico City, Mexico; ¹⁴Royal North Shore Hospital, Sydney, Australia; ¹⁵University Hospital Würzburg, Bavarian Cancer Research Center (BZKF), Würzburg, Germany; ¹⁶Kobe University Hospital, Kobe, Japan; ¹⁷Bristol Myers Squibb, Princeton, NJ, USA; ¹⁸Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

- Patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have poor prognosis and notable morbidity, with deterioration of quality of life^{1,2}
- The addition of cetuximab to chemotherapy improved overall survival (OS) vs chemotherapy alone in the first-line R/M setting³; however, the responses are not durable
- Immunotherapy alone or in combination increased OS benefit, particularly in patients with PD-L1 expression,⁴⁻⁶ and standard of care has shifted to immunotherapy-based treatment⁵
- Nivolumab (NIVO) and ipilimumab (IPI) have distinct but complementary mechanisms of action, and have shown survival benefit and durable responses in several solid tumors⁷⁻¹²
- CheckMate 651 is a randomized, open-label phase 3 trial evaluating NIVO + IPI vs the EXTREME regimen as first-line treatment for platinum-eligible R/M SCCHN

^{1.} Argiris A, et al. *Lancet* 2008;371:1695-1709; 2. Murphy B. *Curr Opin Oncol* 2009;21:242-247; 3. Vermorken JB, et al. *N Engl J Med* 2008;359:1116-1127; 4. Ferris RL, et al. *N Engl J Med* 2016;375:1856-1867; 5. Burtness B, et al. *Lancet* 2019;394:1915-1928; 6. Cohen EEW, et al. *Lancet* 2019;393:156-167; 7. Albiges L, et al. *ESMO Open* 2020;5:e001079; 8. Larkin J, et al. *N Engl J Med* 2019;381:1535-1546; 9. Pardoll DM. *Nat Rev Cancer* 2012;12:252-264; 10. Motzer RJ, et al. *Lancet Oncol* 2019;20:1370-1385; 11. Baas P, et al. *Lancet* 2021; 397:375-386; 12. Paz-Ares L, et al. *J Clin Oncol* 30, 2021 (suppl 15; abstr 9016).

CheckMate 651 study design



NCT02741570. Database lock: June 21, 2021; minimum / median follow-up: 27.3 months / 39.1 months.

^aDetermined by the PD-L1 IHC 28-8 pharmDx assay (Dako); ^bInitial cetuximab dose of 400 mg/m² once only, then cetuximab 250 mg/m² Q1W plus cisplatin 100 mg/m² or carboplatin AUC 5 on day 1, plus fluorouracil 1000 mg/m²/d for 4 days for 6 cycles (Q3W); ^cCetuximab 250 mg/m² Q1W; Q2W maintenance was allowed per local prescribing information; ^dPart of statistical testing hierarchy. BICR, blinded independent central review; CPS, combined positive score; DOR, duration of response; LAD, locally advanced disease; OPC, oropharyngeal cancer; ORR, objective response rate.

Statistical testing hierarchy


- OS in all randomized and CPS \geq 20 populations (primary endpoints) were tested in parallel,^a with equal overall α = 0.025 (two-sided) using stratified log-rank test
 - OS in CPS ≥1 (secondary endpoint) was to be tested at the same α level as CPS ≥20, if and only if OS in CPS ≥20 were positive
 - If OS in all randomized was positive, OS in CPS \geq 20 could be retested with overall α = 0.05
 - If OS in CPS \ge 20 and CPS \ge 1 were both positive, but OS in all randomized failed, OS in all randomized could be retested with overall $\alpha = 0.05$

Baseline characteristics

	All randomized patients		PD-L1 CPS ≥20		
	NIVO + IPI	EXTREME	NIVO + IPI	EXTREME	
	(n = 472)	(n = 475)	(n = 185)	(n = 178)	
Age, median (range), years	61 (24-86)	62 (29-86)	61 (30-83)	61 (31-86)	
Male, %	80	84	80	77	
ECOG PS, ^a %					
0	32	36	35	37	
1	67	63	64	62	
Current or former smoker, %	76	78	72	78	
Disease status, %					
Locally recurrent	28	36	32	35	
Locally recurrent and metastatic	32	24	32	27	
Metastatic	39	40	36	38	
Primary site, %					
Oral cavity	27	28	38	33	
Oropharynx	43	41	39	40	
Hypopharynx	10	12	6	11	
Larynx	21	19	17	16	
OPC p16+, ^{b,c} %	20	20	17	22	
Prior chemotherapy, ^{c,d} %	50	50	44	52	
Tumor PD-L1 expression, ^c %					
<1% or non-evaluable	42	42	8	10	
≥1%	58	58	92	90	
PD-L1 CPS, ^e %					
<1	20	18	-	-	
≥1	75	78	-	-	
≥20	39	38	100	100	

^aECOG PS 2 was reported in 2 and 1 patients in the NIVO + IPI and EXTREME arms respectively; ECOG PS was not reported in 1 patient in the EXTREME arm; ^bp16 status not reported in 1 patient each in both the NIVO + IPI and EXTREME arms; ^cPer interactive response technology; ^dAdjuvant, neoadjuvant, or multimodal therapy; ^e5% and 4% of patients in the NIVO + IPI arm and EXTREME arm, respectively, were non-evaluable for PD-L1 CPS. CPS, combined positive score; OPC, oropharyngeal cancer.

Treatment disposition and subsequent therapies




• The proportion of patients receiving subsequent systemic therapy was similar in the PD-L1 CPS ≥20 population^d

Minimum / median follow-up: 27.3 months / 39.1 months.

^aReasons for not continuing the treatment included disease progression (63%), study drug toxicity (12%), AE unrelated to study drug (9%), other (10%); ^bReasons for not continuing the treatment included disease progression (69%), study drug toxicity (10%), AE unrelated to study drug (6%), other (2%); ^cPercentages based on randomized population; patients may have received more than 1 type of subsequent therapy; ^d46% (NIVO + IPI) and 60% (EXTREME) of patients with CPS \geq 20 received subsequent systemic therapy; 11% and 43%, respectively, received subsequent immunotherapy. CPS, combined positive score.


Primary endpoints: OS with NIVO + IPI vs EXTREME



Minimum follow-up: 27.3 months.

^a95% CI = 12.1-15.8 (NIVO + IPI) and 12.6-15.2 (EXTREME); ^b95% CI = 13.8-22.0 (NIVO + IPI) and 12.3-16.0 (EXTREME); ^cConfidence intervals are adjusted based on the final α levels for each primary endpoint. CPS, combined positive score.


Efficacy in all randomized patients



Minimum follow-up: 27.3 months.

^aPer BICR; ^b95% CI = 2.8-4.2 (NIVO + IPI) and 5.8-7.0 (EXTREME); ^c95% CI = 9.7-29.4 (NIVO + IPI) and 5.4-7.0 (EXTREME). BICR, blinded independent central review; CR, complete response; DOR, duration of response; ORR, objective response rate.


Efficacy in PD-L1 CPS ≥20 population



Minimum follow-up: 27.3 months.

^aPer BICR; ^b95% CI = 3.1–6.9 (NIVO + IPI) and 5.6–8.7 (EXTREME); ^c95% CI = 12.1–NR (NIVO + IPI) and 5.6–10.1 (EXTREME). BICR, blinded independent central review; CR, complete response; DOR, duration of response; ORR, objective response rate.

Efficacy in PD-L1 CPS ≥1 population



Minimum follow-up: 27.3 months.

^aPer BICR; ^b95% CI = 13.7-18.8 (NIVO + IPI) and 11.1-14.6 (EXTREME); ^c95% CI = 2.9-5.4 (NIVO + IPI) and 5.6-7.0 (EXTREME); ^dCR rate = 8%; ^eCR rate = 5%; ^f95% CI = 10.9-32.6 (NIVO + IPI) and 5.6-7.6 (EXTREME). BICR, blinded independent central review; CR, complete response; DOR, duration of response; ORR, objective response rate.

OS subgroup analysis: all randomized patients


- Subgroup	Median OS, mo			
	NIVO + IPI (n = 472)	EXTREME (n = 475)	Unstratified hazard ratio	Unstratified hazard ratio (95% CI)
All randomized (N = 947)	13.9	13.5	0.94 ^a	-•
<65 years (n = 605)	14.8	13.8	0.88	
≥65 and <75 years (n = 285)	12.1	12.3	0.99	_ _
≥75 years (n = 57)	16.0	23.1	1.37	•
Male (n = 777)	14.2	14.0	0.95	
Female (n = 170)	11.6	11.6	0.91	_
ECOG PS 0 (n = 325)	20.1	18.1	0.83	
ECOG PS ≥1 (n = 621)	10.7	11.1	0.97	
Oral cavity (n = 259)	10.9	12.9	0.94	
Oropharynx (n = 396)	16.0	15.0	0.93	
Hypopharynx (n = 101)	13.4	12.5	0.84	
Larynx (n = 190)	15.0	13.3	1.02	_
Current or former smoker (n = 729)	14.2	13.4	0.91	
Never smoker (n = 186)	11.4	14.3	1.13	
OPC p16+ (n = 186) ^b	19.8	23.8	1.19	
OPC p16- or non-OPC (n = 761) ^b	13.1	12.6	0.89	
Prior chemotherapy (n = 474) ^b	14.2	14.2	0.87	
No prior chemotherapy (n = 473) ^b	13.5	13.5	1.00	
Tumor PD-L1 <1% or non-evaluable (n = 401) ^b	11.7	15.5	1.18	<u> </u>
Tumor PD-L1 ≥1% (n = 546) ^b	15.8	12.8	0.80	I
PD-L1 CPS <1 (n = 178)	7.9	17.7	1.66	
PD-L1 CPS ≥1 (n = 727)	15.7	13.2	0.81 ^c	- e -¦
PD-L1 CPS 1–19 (n = 364)	14.5	11.2	0.83	'
PD-L1 CPS ≥20 (n = 363)	17.6	14.6	0.81 ^d	

Minimum follow-up: 27.3 months.

NIVO + IPI ↔ EXTREME

Bold text indicates study stratification factors. ^aStratified HR, 0.95; ^bPer interactive response technology; ^cStratified HR, 0.82; ^dStratified HR, 0.78. CPS, combined positive score; OPC, oropharyngeal cancer.

Patient-reported outcomes: PD-L1 CPS ≥20 population




Completion rates at baseline were 92% vs 81% in the NIVO + IPI and EXTREME arms, respectively; ^aTime to symptom deterioration is defined as time from randomization to first clinically meaningful decline (reduction of \geq 3 points) from baseline in FHNSI-10 score; ^bFHNSI-10 assesses the effects of disease symptoms on functioning and well-being using a 10-item index (pain, lack of energy, swallowing, pain in mouth/throat/neck, trouble breathing, ability to communicate, nausea, eating solid foods, worry about condition worsening, contentedness with quality of life); ^o95% CI = 7.4–31.6 (NIVO + IPI) and 4.3–10.9 (EXTREME); ^dEQ-5D-3L VAS records self-reported health status on a 100-point VAS; 7-point change is a MID; only on-treatment time points with data for \geq 10 patients in either treatment group are shown; not adjusted for multiplicity. 1. Yount S, et al. *Qual Life Res* 2007;16:1615-1626; 2. Pickard AS, et al. *Health Qual Life* 2007;5:70. CPS, combined positive score; EQ-5D-3L VAS, EuroQol five dimension visual analog scale; FHNSI-10, Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom 10-Item Index; MID, minimally important difference; TTSD, time to symptom deterioration.

Safety and exposure summary in all treated patients

	NIVO + IPI (n = 468)		EXTREME (n = 441)	
TRAE, %	Any grade	Grade 3/4	Any grade	Grade 3/4
Any TRAEs	72	28	98	71
TRAEs leading to discontinuation of any component of the regimen	12ª	10	13	9
Serious TRAEs	16	12	28	24
Treatment-related deaths	1 ^b		2°	

- Median (range) duration of therapy was 3.8 (<0.1-24.0) months in the NIVO + IPI arm vs 5.0 (<0.1-50.7) months in the EXTREME arm
- Patients in the NIVO + IPI arm received a median (range) of 8 (1-53) doses of NIVO and 3 (1-18) doses of IPI

Immune-mediated AEs^a with NIVO + IPI



^aEvents in all treated patients; immune-mediated AEs are specific events, regardless of causality and occurring within 100 days of last dose of study drug, for which patients received immunosuppressive medication for treatment of the event, with the exception of endocrine events, which are included regardless of treatment since these events are often managed without immunosuppression.

Summary: NIVO + IPI vs EXTREME

• In CheckMate 651, there was no statistical improvement in OS with NIVO + IPI vs EXTREME in all randomized (HR: 0.95; *P* = 0.4951) as 1L treatment of R/M SCCHN

- OS in the EXTREME control arm was better than expected based on historical data

- In patients with PD-L1 CPS ≥20 or CPS ≥1, NIVO + IPI showed evidence of clinical benefit vs EXTREME as seen with prolonged OS and durable responses
 - Median OS: 17.6 vs 14.6 months (CPS ≥20) and 15.7 vs 13.2 months (CPS ≥1), respectively
 - With NIVO + IPI, more than half of responders were still in response at 18 months in both populations
- NIVO + IPI tended to delay symptom deterioration and clinically improved overall health status
 vs EXTREME in the CPS ≥20 population
- NIVO + IPI had a favorable safety profile vs EXTREME; no new safety signals were observed

ANY QUESTIONS

Thank You

